179 related articles for article (PubMed ID: 37608028)
1. Detection of metastases using circulating tumour DNA in uveal melanoma.
Beasley AB; de Bruyn DP; Calapre L; Al-Ogaili Z; Isaacs TW; Bentel J; Reid AL; Dwarkasing RS; Pereira MR; Khattak MA; Meniawy TM; Millward M; Brosens E; de Klein A; Chen FK; Kiliҫ E; Gray ES
J Cancer Res Clin Oncol; 2023 Nov; 149(16):14953-14963. PubMed ID: 37608028
[TBL] [Abstract][Full Text] [Related]
2. Circulating tumor DNA tracking through driver mutations as a liquid biopsy-based biomarker for uveal melanoma.
Bustamante P; Tsering T; Coblentz J; Mastromonaco C; Abdouh M; Fonseca C; Proença RP; Blanchard N; Dugé CL; Andujar RAS; Youhnovska E; Burnier MN; Callejo SA; Burnier JV
J Exp Clin Cancer Res; 2021 Jun; 40(1):196. PubMed ID: 34134723
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of Circulating Tumor DNA as a Liquid Biomarker in Uveal Melanoma.
de Bruyn DP; van Poppelen NM; Brands T; van den Boom SC; Eikenboom E; Wagner A; van Veghel-Plandsoen MM; Geeven G; Beverloo B; van Rij CM; Verdijk RM; Naus NC; Bagger MM; Kiilgaard JF; de Klein A; Brosens E; Kiliç E
Invest Ophthalmol Vis Sci; 2024 Feb; 65(2):11. PubMed ID: 38319670
[TBL] [Abstract][Full Text] [Related]
4. Early Circulating Tumour DNA Variations Predict Tumour Response in Melanoma Patients Treated with Immunotherapy.
Keller L; Guibert N; Casanova A; Brayer S; Farella M; Delaunay M; Gilhodes J; Martin E; Balagué G; Favre G; Pradines A; Meyer N
Acta Derm Venereol; 2019 Feb; 99(2):206-210. PubMed ID: 30393817
[TBL] [Abstract][Full Text] [Related]
5. Circulating Tumor DNA as a Prognostic Factor in Patients With Resectable Hepatic Metastases of Uveal Melanoma.
Mariani P; Bidard FC; Rampanou A; Houy A; Servois V; Ramtohul T; Pierron G; Chevrier M; Renouf B; Lantz O; Gardrat S; Vincent-Salomon A; Roman-Roman S; Rodrigues M; Piperno-Neumann S; Cassoux N; Stern MH; Renault S
Ann Surg; 2023 Oct; 278(4):e827-e834. PubMed ID: 36847256
[TBL] [Abstract][Full Text] [Related]
6. Circulating tumour DNA predicts response to anti-PD1 antibodies in metastatic melanoma.
Lee JH; Long GV; Boyd S; Lo S; Menzies AM; Tembe V; Guminski A; Jakrot V; Scolyer RA; Mann GJ; Kefford RF; Carlino MS; Rizos H
Ann Oncol; 2017 May; 28(5):1130-1136. PubMed ID: 28327969
[TBL] [Abstract][Full Text] [Related]
7. Tumour-agnostic circulating tumour DNA analysis for improved recurrence surveillance after resection of colorectal liver metastases: A prospective cohort study.
Øgaard N; Reinert T; Henriksen TV; Frydendahl A; Aagaard E; Ørntoft MW; Larsen MØ; Knudsen AR; Mortensen FV; Andersen CL
Eur J Cancer; 2022 Mar; 163():163-176. PubMed ID: 35074652
[TBL] [Abstract][Full Text] [Related]
8. Clinical Application of Circulating Tumor Cells and Circulating Tumor DNA in Uveal Melanoma.
Beasley A; Isaacs T; Khattak MA; Freeman JB; Allcock R; Chen FK; Pereira MR; Yau K; Bentel J; Vermeulen T; Calapre L; Millward M; Ziman MR; Gray ES
JCO Precis Oncol; 2018; 2():. PubMed ID: 32913999
[TBL] [Abstract][Full Text] [Related]
9. Circulating tumor DNA-based molecular residual disease detection for treatment monitoring in advanced melanoma patients.
Eroglu Z; Krinshpun S; Kalashnikova E; Sudhaman S; Ozturk Topcu T; Nichols M; Martin J; Bui KM; Palsuledesai CC; Malhotra M; Olshan P; Markowitz J; Khushalani NI; Tarhini AA; Messina JL; Aleshin A
Cancer; 2023 Jun; 129(11):1723-1734. PubMed ID: 36869646
[TBL] [Abstract][Full Text] [Related]
10. Longitudinal Monitoring of ctDNA in Patients with Melanoma and Brain Metastases Treated with Immune Checkpoint Inhibitors.
Lee JH; Menzies AM; Carlino MS; McEvoy AC; Sandhu S; Weppler AM; Diefenbach RJ; Dawson SJ; Kefford RF; Millward MJ; Al-Ogaili Z; Tra T; Gray ES; Wong SQ; Scolyer RA; Long GV; Rizos H
Clin Cancer Res; 2020 Aug; 26(15):4064-4071. PubMed ID: 32321716
[TBL] [Abstract][Full Text] [Related]
11. Circulating Tumour DNA for Monitoring Treatment Response to Anti-PD-1 Immunotherapy in Melanoma Patients.
Ashida A; Sakaizawa K; Uhara H; Okuyama R
Acta Derm Venereol; 2017 Nov; 97(10):1212-1218. PubMed ID: 28681063
[TBL] [Abstract][Full Text] [Related]
12. Detection of clinical progression through plasma ctDNA in metastatic melanoma patients: a comparison to radiological progression.
Marsavela G; McEvoy AC; Pereira MR; Reid AL; Al-Ogaili Z; Warburton L; Khattak MA; Abed A; Meniawy TM; Millward M; Ziman MR; Calapre L; Gray ES
Br J Cancer; 2022 Feb; 126(3):401-408. PubMed ID: 34373567
[TBL] [Abstract][Full Text] [Related]
13. Detectability of Plasma-Derived Circulating Tumor DNA Panel in Patients Undergoing Primary Treatment for Uveal Melanoma.
Francis JH; Barker CA; Brannon AR; Canestraro J; Robbins M; Swartzwelder CE; Levine S; Law C; Berger MF; Shoushtari A; Abramson DH
Invest Ophthalmol Vis Sci; 2022 Dec; 63(13):17. PubMed ID: 36525262
[TBL] [Abstract][Full Text] [Related]
14. Circulating tumor DNA is a prognostic biomarker in metastatic melanoma patients treated with chemoimmunotherapy and BRAF inhibitor.
Mattila KE; Mäkelä S; Kytölä S; Andersson E; Vihinen P; Ramadan S; Skyttä T; Tiainen L; Vuoristo MS; Tyynelä-Korhonen K; Koivunen J; Kohtamäki L; Aittomäki K; Hernberg M
Acta Oncol; 2022 Oct; 61(10):1263-1267. PubMed ID: 36307938
[TBL] [Abstract][Full Text] [Related]
15. Correlation between circulating tumour DNA and metabolic tumour burden in metastatic melanoma patients.
McEvoy AC; Warburton L; Al-Ogaili Z; Celliers L; Calapre L; Pereira MR; Khattak MA; Meniawy TM; Millward M; Ziman M; Gray ES
BMC Cancer; 2018 Jul; 18(1):726. PubMed ID: 29986670
[TBL] [Abstract][Full Text] [Related]
16. Circulating Tumor DNA Reflects Uveal Melanoma Responses to Protein Kinase C Inhibition.
Park JJ; Diefenbach RJ; Byrne N; Long GV; Scolyer RA; Gray ES; Carlino MS; Rizos H
Cancers (Basel); 2021 Apr; 13(7):. PubMed ID: 33917514
[TBL] [Abstract][Full Text] [Related]
17. Circulating tumour DNA as a biomarker in resectable and irresectable stage IV colorectal cancer; a systematic review and meta-analysis.
Jones RP; Pugh SA; Graham J; Primrose JN; Barriuso J
Eur J Cancer; 2021 Feb; 144():368-381. PubMed ID: 33422803
[TBL] [Abstract][Full Text] [Related]
18. Early detection of metastatic uveal melanoma by the analysis of tumor-specific mutations in cell-free plasma DNA.
Le Guin CHD; Bornfeld N; Bechrakis NE; Jabbarli L; Richly H; Lohmann DR; Zeschnigk M
Cancer Med; 2021 Sep; 10(17):5974-5982. PubMed ID: 34291585
[TBL] [Abstract][Full Text] [Related]
19. Circulating Nucleic Acids Are Associated With Outcomes of Patients With Pancreatic Cancer.
Bernard V; Kim DU; San Lucas FA; Castillo J; Allenson K; Mulu FC; Stephens BM; Huang J; Semaan A; Guerrero PA; Kamyabi N; Zhao J; Hurd MW; Koay EJ; Taniguchi CM; Herman JM; Javle M; Wolff R; Katz M; Varadhachary G; Maitra A; Alvarez HA
Gastroenterology; 2019 Jan; 156(1):108-118.e4. PubMed ID: 30240661
[TBL] [Abstract][Full Text] [Related]
20. Dynamic monitoring of cerebrospinal fluid circulating tumor DNA to identify unique genetic profiles of brain metastatic tumors and better predict intracranial tumor responses in non-small cell lung cancer patients with brain metastases: a prospective cohort study (GASTO 1028).
Li M; Chen J; Zhang B; Yu J; Wang N; Li D; Shao Y; Zhu D; Liang C; Ma Y; Ou Q; Hou X; Chen L
BMC Med; 2022 Nov; 20(1):398. PubMed ID: 36372873
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]